Skip to main content
Premium Trial:

Request an Annual Quote

Whatman, GE Healthcare, VigeneTech, Epicentre Biotechnologies, Affymetrix, London Genetics

Premium
Whatman, part of GE Healthcare, and VigeneTech last week announced the launch of custom software to analyze Whatman FAST Quant samples. The customized original-equipment-manufactured software from VigeneTech provides high-quality image quantification and enhances the automation for Whatman FAST Quant protein array image and data analysis, the companies said.
 
A customized version of MicroVigene from VigeneTech now enables FAST Quant users to analyze fluorescent immunoassay results from multiplexed platforms. More accurate spot finding in an array format assures increased accuracy of assay results, the duo said.
 

 
Epicentre Biotechnologies this week launched its TargetAmp 1-Round Biotin-aRNA Amplification Kit 105, which produces biotin-aRNA from as little as 25 nanograms of total RNA, the company claims.
 
The labeled RNA yields high-quality results on Affymetrix GeneChip arrays as judged by signal intensity and present calls, Epicentre said.
 

 
London Genetics this week launched its molecular cytogenetics testing service. The new service covers all aspects of molecular and conventional cytogenetics.
 
According to the firm, the service can already provide techniques such as array comparative genome hybridization, copy number variation validation, G-banding, and fluorescence in situ hybridization analyses.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.